Molecular Partners

Update in progress

MOLN (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Molecular Partners AG is a Swiss clinical-stage biotechnology company that designs and develops designed ankyrin repeat proteins (DARPins) for oncology. Its pipeline includes MP0317 (Phase 2 solid tumors), MP053 (Phase 1 acute myeloid leukemia), MP0712 (212Pb Radio-DARPin targeting DLL3 for SCLC and neuroendocrine tumors), MP0726 (Radio-DARPin for ovarian and MSLN-expressing cancers), MP0621 (Switch-DARPin for conditioning), and a broader Radio-DARPin platform. Partners include Orano Med SAS and Eckert & Ziegler SE. Founded 2004, Schlieren, Switzerland.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive